ASLN 주가 차트
ASLN 수입
Aslan Pharmaceuticals Ltd
$0.6
-14.27%
$-0.09
오늘 기준:Apr 28, 11:46:41 GMT-4
뒤로
Aslan Pharmaceuticals Ltd (ASLN) 수입
최신 수익 결과: Q1 '24
보고됨: 2024-05-31
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
ASLN의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Aslan Pharmaceuticals Ltd ASLN의 지난 분기 매출 실적은 어땠나요?
Aslan Pharmaceuticals Ltd의 매출 추정치는 얼마인가요?
Aslan Pharmaceuticals Ltd의 수익 품질 점수는 얼마인가요?
Aslan Pharmaceuticals Ltd는 언제 수익을 보고하나요?
Aslan Pharmaceuticals Ltd의 예상 수익은 얼마인가요?
Aslan Pharmaceuticals Ltd은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.6999
시가
$0.63
일일 범위
$0.6 - $0.6999
52주 범위
$0.6 - $4.66
거래량
769.8K
평균 거래량
680.5K
배당수익률
--
EPS(TTM)
-0.03
시가총액
$1.6M
ASLN란 무엇인가요?
ASLAN is a pharmaceutical company that develops novel medicines for global markets. The firm's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. The company is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The firm is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The firm is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.